Form 4 · AMGN
Amgen director Omar Ishrak reports an award of about 152 shares
Part of a grouped insider digest: see all related filings with totals →
Omar Ishrak, an Amgen director, filed a Form 4 on Nov 9, 2026 at 7:46 PM ET reporting transactions on Nov 6, 2026.
The filing reports about 152 shares in a grant or award (code A).
After these transactions, the filing lists about 7,682 shares held directly.
Effect on holdings
Taken together, the rows reported here raised Omar Ishrak's directly held shares by 2.0%, from about 7,530 to about 7,682.
Reporting person
- Omar Ishrak, director (as filed: ISHRAK OMAR)
Transactions as reported
| Date | Code | Security | Shares | Price | Acquired or disposed | Held after | Ownership |
|---|---|---|---|---|---|---|---|
| 2026-11-06 | A | Common Stock | 152 | Acquired | 7,682 | Direct |
Codes: P purchase, S sale, A grant or award, M/X/C exercise or conversion, F shares withheld for taxes or the exercise price, G gift. Prices are as reported; some are weighted averages of several trades.
Source
- Form 4 filed Nov 9, 2026 (document)
- Filing index on SEC EDGAR (all documents and exhibits)
Amgen company file → · More Amgen filings
Disclosures
- Editor holdings in AMGN
- The editor holds no position in Amgen (AMGN). As of Nov 11, 2026.
- Last updated
- Nov 10, 2026
A summary of a public filing for general education, the same for every reader. Not a recommendation to buy, sell or hold AMGN.